Enterprise Value
1.552B
Cash
380.7M
Avg Qtr Burn
-34.94M
Short % of Float
4.56%
Insider Ownership
0.13%
Institutional Own.
44.85%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Imetelstat (GRN163L) Details Hematologic malignancies, Myelodysplastic syndrome | NDA Submission | |
Imetelstat (GRN163L) Details MF (Myelofibrosis) | Phase 3 Interim Update |